Loading clinical trials...

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors | Clinical Trials | Clareo Health

TERMINATEDNA

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy

NCT00875004•Institut du Cancer de Montpellier - Val d'Aurelle

View on ClinicalTrials.gov

Summary

RATIONALE: Epoetin beta may cause the body to make more red blood cells and may prevent or reduce side effects in patients undergoing chemotherapy for solid tumors. PURPOSE: This clinical trial is studying how well epoetin beta works in patients undergoing chemotherapy for solid tumors.

Detailed Description

OBJECTIVES: Primary * Identify factors predictive of treatment failure in patients with solid tumors treated with epoetin beta while undergoing chemotherapy. Secondary * Evaluate the impact of achieving target hemoglobin levels (i.e., hemoglobin \> 11 g/dL) after 8 weeks of treatment with epoetin beta. * Evaluate changes in hemoglobin levels from baseline to after 8 weeks of treatment with epoetin beta. * Evaluate the tolerability of epoetin beta in these patients. * Evaluate the quality of life of these patients. OUTLINE: This is a multicenter study. Patients receive epoetin beta subcutaneously once a week for ≥ 8 weeks in the absence of disease progression or unacceptable toxicity. Patients complete a quality-of-life questionnaire (FACT-An) at baseline and after 8 weeks of treatment.

Eligibility

Age

18 - 120 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age \> 18 years
•Hemoglobin levels between \[ \> 9g/dl - \< 11 g/dl \] .
•Patient requiring erythropoietine beta treatment for a foreseeable duration of at least 8 weeks under the same chemotherapy protocol.
•Patient with cancer undergoing chemotherapy
•Patient without EPO within 6 months prior to current chemotherapy.
•WHO 2 performance status (Appendix 1).
•Patient information and signature of informed consent or legal representative

Exclusion Criteria

•Hemoglobin \< 9 g/dl or \> 11 g/dl
•Patient with cancer not treated with chemotherapy (targeted therapy, hormone therapy, etc…)
•Patient with cancer treated with concomitant radiation chemotherapy.
•Co-treated with Epo beta and scheduled transfusion prior to inclusion.
•Hypersensitivity to the active substance or one of the NeoRecormon excipients®
•Poorly controlled high blood pressure
•Pregnant woman, likely to be pregnant or breastfeeding,
•Persons deprived of liberty or under guardianship,
•Unable to undergo medical follow-up for geographic, social or psychological reasons.

Locations (1)

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

Montpellier, France

Key Dates

Start Date

December 7, 2007

Primary Completion Date

December 31, 2011

Completion Date

December 31, 2011

Last Updated

June 26, 2024

Enrollment

ACTUAL participants

Conditions

AnemiaUnspecified Adult Solid Tumor, Protocol Specific

Interventions

epoetin beta

BIOLOGICAL

systemic chemotherapy

DRUG

quality-of-life assessment

PROCEDURE

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

NCT05012111

Severe Aplastic AnemiaTelomere Biology Disorders+1 more

View study

RECRUITINGPHASE2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

NCT03520647

Severe Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

Inclusion Criteria

Exclusion Criteria

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Guideline Adherence for Preoperative Anemia Management in a PAC

Revolade Tablets Specified Drug-use Survey

National Longitudinal Cohort of Hematological Diseases

Familial Investigations of Childhood Cancer Predisposition